ACL-508 / Chong Kun Dang, Archela - LARVOL DELTA

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects (clinicaltrials.gov) - P1 | N=88 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed | Trial completion date: Sep 2022 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Jul 2023

First-in-human • Trial completion • Trial completion date • Trial primary completion date

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical

First-in-human • New P1 trial

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial

A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical | Trial completion date: May 2021 ➔ Sep 2022 | Trial primary completion date: May 2021 ➔ Sep 2022

First-in-human • Trial completion date • Trial primary completion date

A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants (clinicaltrials.gov) - P1 | N=44 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed

Trial completion

Differentiated Pharmacologic Profile of ACL-508 in Cholesteryl Ester Transfer Protein-Expressing Preclinical Models (AHA 2026) - No abstract available

Late-breaking abstract • Preclinical • Atherosclerosis • Cardiovascular • Hematological Disorders • Thrombosis